Baxter International Inc. (BAX) Earnings Call Transcripts

Baxter International Inc.'s Latest Earnings Call - Q3 FY2026

In the third quarter of 2026, Baxter International Inc. reported global sales of approximately $3 billion, reflecting a 5% increase on both a reported and organic basis. Adjusted earnings per diluted share were $0.58, which exceeded expectations but represented a year-over-year decline due to prior tax benefits. Management raised their full-year guidance for organic sales growth to a range of 3% to 4% and adjusted earnings per share to $2.05 to $2.15, indicating increased confidence in the company's turnaround efforts.

Reported metrics

Guidance from management

Baxter raised its full-year guidance for organic sales growth to a range of 3% to 4% and adjusted earnings per diluted share to $2.05 to $2.15, reflecting increased confidence in the company's performance.

What management said

And Lilly, just to add on a little bit to this. As a reminder, our exposure to fuel oil is much less with the divestiture of our Kidney Care business. And to John's point, we've taken a very proactive approach and our teams are aligned around mitigating cost actions, driving engagement with suppliers, looking at efficiencies in the business. And so overall, again, pleased with the progress. We've got more work to do ...

And Rick, with respect to pricing, so the commentary was when you think about operating income dollars year-over-year, there was less contribution from pricing. And it's really a prior year story. So if you recall last year, we saw the benefit from 2 of our GPO renewals. So this mostly impacted the MPT segment. And so this year, it's really kind of the absence of that outsized benefit when you think about the year-ov...

What analysts pressed on

Analysts expressed concerns regarding the impact of the cephalosporin product discontinuation and its potential headwind on earnings for 2027. Additionally, there were questions about the ongoing supply chain challenges and their effects on future growth.

Main topics on the call

• Revenue Growth Acceleration — Baxter's third quarter global sales totaled approximately $3 billion, an increase of 5% on both a reported and organic basis. Management noted, "We saw broad-based growth, with every division contributing and both segmen...
• Adjusted Earnings Performance — Adjusted earnings were reported at $0.58 per diluted share, reflecting a year-over-year decline of 16% due to higher effective tax rates. Management stated, "While this exceeded our expectations, it represents an expecte...
• Guidance Update — Baxter raised its full-year outlook for organic sales growth to a range of 3% to 4% and adjusted earnings per diluted share to $2.05 to $2.15. This adjustment was made as management expressed greater confidence in the co...
• Strategic Priorities Progress — Management highlighted advancements in stabilizing the business, strengthening the balance sheet, and embedding continuous improvement. They noted, "We are seeing more consistent execution and further indicators of impro...

Read the full Baxter International Inc. transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 89 Baxter International Inc. earnings call transcripts on record, spanning January 13, 2020 to October 29, 2026. Based on this history, Baxter International Inc. reports quarterly. The most recent call on file is dated October 29, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BAX

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

89

First call

January 13, 2020

Most recent

October 29, 2026

Reporting cadence

quarterly